HighTide Therapeutics places big IPO bet on “affluenza” drug
The company is pouring almost all its R&D budget into producing a metabolic drug to treat several conditions including diabetes Key Takeaways: With no products yet on the market, HighTide…
Recent Articles
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
WuXi Biologics hatches new baby with ADC drug unit IPO
2269.HK
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
-
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
-
RemeGen hopes for pain relief from expanded drug uses
9995.HK 688331.SHG
-
Everest reaches new heights on growing drug sales
1952.HK
Discover hidden China stock gems in our weekly newsletter